Product Description
Discover unparalleled access to Abiraterone Acetate Tablets, available in 250 mg or 500 mg strengths. For a limited time, benefit from a reduced price on a first-rate treatment strictly administered under a qualified oncologists supervision. Each film-coated, oval tablet is US FDA/EMA/WHO compliant and supports adults battling metastatic castration-resistant prostate cancer (mCRPC). Packed in bottles of 120 or as specified, this remarkable anti-androgen oral therapy offers unrivaled efficacy and safetybacked by stringent regulatory standards. Seize this exceptional offer before it ends!
Application and Usage Domains
Abiraterone Acetate Tablets are primarily designed for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in adults. Tailored for oncological settings, these tablets are utilized under strict medical supervision. While their central application is in prostate cancer therapy, they can also form part of broader cancer care regimens where anti-androgen therapy is indicated. The oral, film-coated formulation ensures convenient administration in both hospital and outpatient programs, improving therapy flexibility.
FOB Port, Domestic Market, and Certifications
Transport services for Abiraterone Acetate Tablets are streamlined through leading FOB ports across India, facilitating reliable global goods transport. The main domestic market centers in India, accommodating distributors, suppliers, and wholesalers. These film-coated oral tablets have secured certifications and approvals as per US FDA, EMA, and WHO guidelines. Efficient domestic and international shipment ensures unmatched quality and timely delivery, maintaining product integrity from manufacturing to healthcare facilities.
FAQs of Abiraterone Acetate Tablets:
Q: How should Abiraterone Acetate Tablets be administered for optimal effectiveness?
A: Abiraterone Acetate Tablets must be administered orally under the supervision of a qualified oncologist. It is critical to follow the prescribed dosage and administration guidelines for the best therapeutic outcome.
Q: What medical condition are these tablets specifically used to treat?
A: These tablets are specifically indicated for metastatic castration-resistant prostate cancer (mCRPC) in adult patients, offering a pivotal role in advanced prostate cancer care.
Q: When is it appropriate to consider starting Abiraterone Acetate Tablets therapy?
A: Abiraterone Acetate Tablets are prescribed when a patient has been diagnosed with mCRPC and other treatment options may be less effective. Your oncologist will determine the right time to initiate therapy based on clinical evaluation.
Q: Where should Abiraterone Acetate Tablets be stored for maximum shelf life?
A: The tablets should be stored below 30C, protected from moisture and light, to maintain their potency and extend their shelf life up to 24-36 months as indicated.
Q: What regulatory steps ensure the safety and compliance of these tablets?
A: Abiraterone Acetate Tablets are developed and distributed in accordance with US FDA, EMA, and WHO guidelines, guaranteeing strict quality control and patient safety.
Q: How does oral administration benefit patients?
A: Oral administration allows for more flexible treatment settings, including both hospital and outpatient environments, enhancing patient comfort and therapy adherence.